Serum Albumin, E.g., Bsa, Hsa, Etc. Patents (Class 530/363)
-
Publication number: 20120277162Abstract: In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.Type: ApplicationFiled: March 15, 2012Publication date: November 1, 2012Applicant: VASGENE THERAPEUTICS, INC.Inventors: Valery Krasnoperov, Nathalie Kertesz, Ramachandra Reddy, Parkash Gill, Sergey Zozulya
-
Publication number: 20120269828Abstract: The present invention relates to anti-drug vaccines based on conjugates between the drug and a non-immunogenic carrier protein. In preferred embodiments, it provides for anti-cocaine vaccines and their use to diminish the effects and/or use of cocaine in a subject.Type: ApplicationFiled: April 20, 2012Publication date: October 25, 2012Applicant: The Trustees of Columbia University in the City of New YorkInventors: Shi-Xian Deng, Donald W. Landry, Gavreel Kalantarov, Trakht IIya
-
Publication number: 20120264157Abstract: Anionic acid-labile surfactants may generally comprise compounds represented by the formula: wherein R1 is independently selected from —(CH2)0-9CH3, R2 is selected from the group consisting of —H and —(CH2)0-5CH3, Y is an anion, X is a cation, and n is an integer from 1 to 8. Methods of making and using the anionic acid-labile surfactants are also described. The anionic acid-labile surfactants may be used to facilitate the solubilization of proteins and other molecules in an aqueous environment.Type: ApplicationFiled: June 25, 2012Publication date: October 18, 2012Applicant: Protea Biosciences, Inc.Inventors: Matthew Jacob Powell, Trust Tariro Razunguzwa, George Augustine O'Doherty, Miaosheng Li
-
Publication number: 20120263739Abstract: The invention relates to anti-integrin antibodies which are covalently linked to nanoparticles, wherein these nanoparticles were prior loaded with chemotherapeutic/cytotoxic agents. The antibody-chemotherapeutic agent-nanoparticle conjugates according to the invention, especially wherein the antibody is MAb DI17E6 and the cytotoxic agent is doxorubicin show a significant increase of tumor cell toxicity.Type: ApplicationFiled: October 21, 2010Publication date: October 18, 2012Applicant: MERCK PATENT GMBHInventors: Klaus Langer, Marion Anhorn, Joerg Kreuter, Florian Rothweiler, Hagen von Briesen, Sylvia Wagner, Martin Michaelis, Jindrich Cinatl
-
Publication number: 20120264158Abstract: Anionic acid-labile surfactants may generally comprise compounds represented by the formula: wherein R1 is independently selected from —(CH2)0-9CH3, R2 is selected from the group consisting of —H and —(CH2)0-5CH3, Y is an anion, X is a cation, and n is an integer from 1 to 8. Methods of making and using the anionic acid-labile surfactants are also described. The anionic acid-labile surfactants may be used to facilitate the solubilization of proteins and other molecules in an aqueous environment.Type: ApplicationFiled: June 25, 2012Publication date: October 18, 2012Applicant: Protea Biosciences, Inc.Inventors: Matthew Jacob Powell, Trust Tariro Razunguzwa, George Augustine O'Doherty, Miaosheng Li
-
Publication number: 20120258071Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.Type: ApplicationFiled: April 13, 2012Publication date: October 11, 2012Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin G. P. Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
-
Publication number: 20120258077Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.Type: ApplicationFiled: June 14, 2012Publication date: October 11, 2012Applicant: Theraclone Sciences, Inc.Inventors: Matthew Moyle, Jennifer Mitcham
-
Publication number: 20120244163Abstract: Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways.Type: ApplicationFiled: April 10, 2012Publication date: September 27, 2012Applicants: DYAX CORP., MERRIMACK PHARMACEUTICALS, INC.Inventors: Birgit SCHOEBERL, Ulrik NIELSEN, Arthur J. KUDLA, Arumugam MURUGANANDAM, David BUCKLER, Alexey Alexandrovich LUGOVSKOY, Jonathan Basil FITZGERALD, Lihui XU, Neeraj KOHLI
-
Publication number: 20120244634Abstract: The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin.Type: ApplicationFiled: June 7, 2012Publication date: September 27, 2012Applicants: KAGOSHIMA UNIVERSITY, SYSMEX CORPORATIONInventors: Hiroyuki KABATA, Hideki TAKAHASHI, Ikuro MARUYAMA, Rena TSURUOKA
-
Publication number: 20120244577Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.Type: ApplicationFiled: March 2, 2012Publication date: September 27, 2012Applicant: Zymeworks Inc.Inventors: Surjit Bhimarao Dixit, Igor Edmundo Paolo D'Angelo, David Kai Yuen Poon
-
Publication number: 20120237998Abstract: We describe methods that allow either carbodiimides or other carboxyl-reactive substances to be mixed with solutions of carboxylic acids or phosphates or amines or combinations thereof, so as to form a homogeneous mixture which is then dried, preferably in a freeze drying process. The mixture is then contacted with an entity, which preferably involves the dissolution of the mixture with a buffered solution of the entity, so as to initiate a conjugation reaction between the entity and a component in the mixture.Type: ApplicationFiled: March 15, 2011Publication date: September 20, 2012Applicant: INNOVA BIOSCIENCES LIMITEDInventors: Nicholas Gee, Annamaria Draghi
-
Publication number: 20120225087Abstract: The present invention provides novel nicotine hapten compounds and nicotine immunoconjugates which can be used for in vivo production of antibodies that specifically bind to nicotine. The invention also provides methods of using vaccines comprising the nicotine immunoconjugates in active or passive immunization protocols. The compositions and methods of the invention are useful for prevention and treatment of nicotine addiction.Type: ApplicationFiled: September 14, 2010Publication date: September 6, 2012Applicant: The Scripps Research InstituteInventor: Kim D. Janda
-
Publication number: 20120220489Abstract: The present invention provides a calibration reagent comprising a peptide conjugated to a protein carrier via a linker, wherein said peptide comprises an epitope of interest and the use thereof.Type: ApplicationFiled: November 12, 2010Publication date: August 30, 2012Inventors: Maziar Assadi Gehr, Everson Nogoceke
-
Publication number: 20120219972Abstract: The present invention provides an isolated Ehrlichia peptide and therapeutic and diagnostic uses therefor.Type: ApplicationFiled: January 31, 2012Publication date: August 30, 2012Applicant: The Board of Regents of The University of Texas SystemInventors: Sunil Thomas, David H. Walker
-
Patent number: 8252747Abstract: A tissue adhesive sealant includes a cross-linkable protein in a solution that when combined with a cross-linking agent solution including an aldehyde and amino acid containing species reactive with the aldehyde cross-links to form a seal. The sealant is well suited for bonding tissue alone or in combination with a patch. The ratio between the aldehyde and the amino acid containing species is between 20:1 and 1:1 on an aldehyde moiety:amino acid or peptide subunit molar basis. Particularly strong seals are formed when the protein and cross-linking agent are present in a molar ratio of between 15:1 and 1:1.Type: GrantFiled: July 27, 2009Date of Patent: August 28, 2012Inventors: Johan Lowinger, Bruno Lowinger, Frank DeLustro, David Cox, David A. Browdie
-
Publication number: 20120213782Abstract: In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.Type: ApplicationFiled: April 9, 2012Publication date: August 23, 2012Applicant: Acceleron Pharma, Inc.Inventors: Jasbir Seehra, John Knopf
-
Publication number: 20120208213Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.Type: ApplicationFiled: December 20, 2011Publication date: August 16, 2012Applicant: RANDOX LABORATORIES LIMITEDInventors: Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
-
Publication number: 20120208294Abstract: The invention relates to novel immunogens, antibodies, methods and kits for use in immunoassays to detect and quantify zaleplon, metabolites of zaleplon and indiplon. These are the first described immunoassays for these compounds and have greater sensitivity than alternative analytical techniques.Type: ApplicationFiled: July 16, 2010Publication date: August 16, 2012Applicant: RANDOX LABORATORIES LTD.Inventors: Elouard Benchikh, Stephen Peter Fitzgerald, Philip Andrew Lowry, Ivan Robert Mcconnell
-
Publication number: 20120183549Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.Type: ApplicationFiled: November 7, 2011Publication date: July 19, 2012Applicant: NOVARTIS AGInventors: Michelle BRADLEY, Zarin BROWN, Steven John CHARLTON, Karen CROMIE, Bruno DOMBRECHT, Soren STEFFENSEN, Gino VAN HEEKE
-
Publication number: 20120171747Abstract: The present invention relates to microspheres comprising protein signal precursor molecules, or a carrier protein bonded to signal precursor molecules, wherein said signal precursor molecules are activatable to generate a detectable signal whilst remaining bonded to the carrier protein. Also disclosed is a method of making such microspheres comprising the steps of mixing protein molecules with a matrix former in solution; adding a reducing reagent to the mixture; removing the reducing reagent; and removing the matrix former to leave microspheres of protein molecules. Also disclosed are bioassay methods using the microspheres to provide signal amplification, including an amplification cycling procedure.Type: ApplicationFiled: June 10, 2010Publication date: July 5, 2012Applicant: Supernova Diagnostics, Inc.Inventors: Wing Cheung Mak, Ling Wai Wong, Pui YeeCangel Chan, Reinhard Renneberg
-
Publication number: 20120164145Abstract: Helicobacter pylori, one of the most common human pathogens, is associated with the development of human chronic gastritis, peptic ulcers and gastric cancer. The invention relates to a ?1,6-glucan-containing Helicobacter pylori compound comprising the structure of Formula (I): wherein R is a ?-DDHep-3-?-L-Fuc-3-?-GlcNAc trisaccharide substituted with an ?1,6-glucan linked to an ?1,3-DD-heptan, and wherein the last DD-Hep residue of ?1,3-DD-heptan is capped with ?-GlcNAc residue. Compositions comprising the compound, uses of the compound, and antibodies raised against the compound are also described.Type: ApplicationFiled: July 30, 2010Publication date: June 28, 2012Inventors: Eleanora Altman, Blair A. Harrison, Vandana Chandan
-
Publication number: 20120164146Abstract: An isolated peptide of 12-20 amino acids in length comprising the amino acid sequence SEQ ID NO:1, wherein the serine residue (S) at position 8 of SEQ ID NO:1 is phosphorylated, is provided. Also provided is a human monophosphorylated alpha-enolase isoform wherein the serine residue (S) at position 419 of the human alpha-enolase amino acid sequence (SEQ ID NO:2) is phosphorylated and in which other post-translational modifications may be present. Further provided are antibodies capable of specifically binding the peptide and/or the isoform of the invention. The peptide, the isoform and the antibodies of the invention may be used in the diagnosis and/or amelioration and/or treatment of pancreatic adenocarcinoma.Type: ApplicationFiled: September 9, 2010Publication date: June 28, 2012Applicants: NATIMAB THERAPEUTICS S.R.L.Inventors: Francesco Novelli, Barbara Tomaino, Paola Cappello
-
Publication number: 20120156235Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.Type: ApplicationFiled: December 23, 2009Publication date: June 21, 2012Applicant: MEDIMMUNE, LLC.Inventors: Josephine McAuliffe, Frances Palmer-Hill, Qing Zhu, Joann Suzich
-
Publication number: 20120141590Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.Type: ApplicationFiled: September 30, 2011Publication date: June 7, 2012Inventors: Michael Malakhov, Fang Fang
-
Publication number: 20120135912Abstract: The invention provides novel 2D-VCAM-1 variant polypeptides and conjugates thereof that bind human VLA4. The invention also provides related polynucleotides, compositions, vectors, host cells, and methods.Type: ApplicationFiled: May 10, 2011Publication date: May 31, 2012Applicant: PERSEID THERAPEUTICS LLCInventors: MADAN M. PAIDHUNGAT, AMULYA NANISETTI, THOMAS BOUQUIN, KIM VILBOUR ANDERSEN, STEVEN J. CHAPIN, CLAUS KREBBER, RONG A. FAN, DANIEL MALASHOCK, AMY BRIDEAU-ANDERSEN, ERIK KARRER, BRUCE DEVENS, STEVEN H. BASS
-
Publication number: 20120128624Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.Type: ApplicationFiled: December 15, 2011Publication date: May 24, 2012Inventors: Zailin Yu, Yan Fu
-
Publication number: 20120129766Abstract: The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: ApplicationFiled: November 15, 2011Publication date: May 24, 2012Applicants: IRM LLC, NOVARTIS AGInventors: Brian R. BOETTCHER, Shari L. CAPLAN, Douglas S. DANIELS, Bernhard H. GEIERSTANGER, Norio HAMAMATSU, Stuart LICHT, Andreas LOEW, Stephen Craig WELDON
-
Publication number: 20120121591Abstract: Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.Type: ApplicationFiled: March 19, 2010Publication date: May 17, 2012Applicant: Amgen Inc.Inventors: John K. Sullivan, Leslie P. Miranda, Colin V. Gegg, Shaw-Fen Sylvia Hu, Edward J. Belouski, Justin K. Murray, Hung Nguyen, Kenneth W. Walker, Taruna Arora, Frederick W. Jacobsen, Yue-Sheng Li, Thomas C. Boone
-
Publication number: 20120123096Abstract: Methods are described for improvement of the serum half life of therapeutic nucleic acids by 3? conjugation to useful target proteins, or other large molecules with useful function. In one embodiment, a 3? A, C or G overhang is added to ds-DNA and the primary amines conjugated using biocompatible bifunctional linkers to proteins. The resulting nucleic acid-3? conjugates are serum nuclease-resistant and retained in vivo for long periods without rapid kidney clearance. Further, the choice of conjugate imparts additional functionality to the nucleic acid-3? conjugate.Type: ApplicationFiled: March 2, 2010Publication date: May 17, 2012Inventors: John G. Bruno, Judson C. Miner
-
Publication number: 20120122691Abstract: Disclosed are composites that comprise regenerated cellulose, a first active substance, a second active substance, and a linker. Methods for preparing the composites that involve the use of ionic liquids are also disclosed. Articles prepared from the disclosed composites and methods of using them are further disclosed.Type: ApplicationFiled: June 5, 2007Publication date: May 17, 2012Inventors: Daniel T. Daly, Scott K. Spear, Megan B. Turner, Whitney Lauren Hough, Robin D. Rogers
-
Publication number: 20120115244Abstract: Methods of assaying for (i) a pterin by immunoassay employing a pterin as capture agent, (ii) neopterin by chemiluminescent microparticle immunoassay (CMIA) employing an anti-neopterin antibody (Ab) as capture agent, (iii) neopterin by an immunoassay (IA) employing an acridinium (Acr)-labeled anti-neopterin Ab as conjugate, and (iv) neopterin by an IA employing Acr-labeled neopterin as tracer; an Acr-labeled anti-neopterin Ab; a conjugate/complex comprising anti-neopterin Ab and a carrier scaffold; a conjugated pterin; a conjugate comprising an Acr-labeled pterin and a carrier scaffold; an immunogen comprising neopterin and a carrier protein; a conjugate comprising such an immunogen and an Acr compound; an immunogen comprising a carrier protein and a neopterin hapten; a conjugate comprising such an immunogen and an Acr compound; a kit for assaying a pterin comprising a pterin as a capture agent and instructions for IA; and a kit for assaying neopterin comprising an anti-neopterin Ab as a capture agent and insType: ApplicationFiled: November 9, 2010Publication date: May 10, 2012Applicant: ABBOTT LABORATORIESInventors: Maciej Adamczyk, R. Jeffrey Brashear, Stephen C. Hsu, Phillip G. Mattingly
-
Publication number: 20120114682Abstract: Compositions and methods for targeting substances to fibrinogen, fibrin monomers, or fibrin polymers are provided. These compositions and methods generally involve the use of fibrin knob peptides that bind fibrin(ogen), which can be used to detect fibrin(ogen) and modulate fibrin polymerization and fibrinolysis.Type: ApplicationFiled: July 9, 2010Publication date: May 10, 2012Inventor: Thomas Harrison Barker
-
Patent number: 8168756Abstract: Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.Type: GrantFiled: October 22, 2009Date of Patent: May 1, 2012Assignee: ARK Diagnostics, Inc.Inventors: Johnny Jose Valdez, Byung Sook Moon, Ki Chung, Alejandro A. Orozco
-
Publication number: 20120100074Abstract: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).Type: ApplicationFiled: March 22, 2010Publication date: April 26, 2012Inventors: Rodger Smith, Palanisamy Kanakaraj, Bridget A. Cooksey, Viktor Roschke, Craig Rosen
-
Publication number: 20120101256Abstract: The invention relates to a method for providing a multispecific peptide ligand comprising a polypeptide covalently linked to a molecular scaffold at three or more amino acid residues and capable of binding to two or more separate targets, comprising the steps of: (a) providing a first repertoire of polypeptides, each polypeptide comprising two or more reactive groups capable of covalent linkage to a molecular scaffold, and at least one loop which comprises a sequence of two or more amino acids subtended between two of said reactive groups; (b) providing a second repertoire of polypeptides as described in (a); (c) joining at least one loop of one or more members of the first repertoire to at least one loop of one or more members of the second repertoire to form at least one polypeptide comprising two loops, and (d) conjugating the composite polypeptide(s) to a molecular scaffold at at least three amino acid positions.Type: ApplicationFiled: February 4, 2010Publication date: April 26, 2012Applicant: Medical Research CouncilInventors: Gregory Paul Winter, Christian Heinis, Elise Bernard, David Loakes, John Tite, Marina Vaysburd, Daniel Paul Teufel, Lutz Riechmann
-
Publication number: 20120094909Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: ApplicationFiled: April 13, 2011Publication date: April 19, 2012Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
-
Publication number: 20120094316Abstract: The invention relates to an immunoassay method and kit for the detection and/or the determination of mephedrone, mephedrone metabolites and related compounds. The invention is underpinned by a novel antibody, derived from a novel immunogen, that is sensitive and binds to mephedrone, mephedrone metabolites and related compounds.Type: ApplicationFiled: October 18, 2011Publication date: April 19, 2012Inventors: Robert Ivan McConnell, Elouard Benchikh, Philip Andrew Lowry, Stephen Peter Fitzgerald
-
Patent number: 8158857Abstract: The invention is directed to monocot plant seed products comprising human serum albumin, and to methods of making said monocot plant seed products comprising human serum albumin and to therapeutic compositions comprising them.Type: GrantFiled: March 31, 2010Date of Patent: April 17, 2012Assignee: Ventria BioscienceInventors: Ning Huang, Raymond L. Rodriguez, Frank E. Hagie, David M. Stalker
-
Publication number: 20120088312Abstract: Novel conjugates and immunogens derived from vincristine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of vincristine in biological fluids.Type: ApplicationFiled: October 8, 2010Publication date: April 12, 2012Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Daniel J. Cline
-
Publication number: 20120083455Abstract: Disclosed are a human serum albumin-siRNA carrier system having siRNA bound to human serum albumin and a user thereof, and especially, human serum albumin-siRNA carrier system, which has a biodegradable covalent bond between human serum albumin polymer and siRNA and is stable in a living body, and a user thereof. The human serum albumin-siRNA carrier system having the biodegradable covalent bond between the human serum albumin and the siRNA exhibits high siRNA delivery efficiency to a target site in the living body. Therefore, the human serum albumin-siRNA carrier system may allow siRNA for therapy to be efficiently delivered to a target site such as cancer tissues in the living body even by being administrated in a relatively low concentration, which may result in a wide use for therapies of various diseases.Type: ApplicationFiled: September 26, 2011Publication date: April 5, 2012Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Kwangmeyung KIM, Ick Chan KWON, Kuiwon CHOI, In Chan YOUN, Myung Sook HUH, Sojin LEE
-
Publication number: 20120076728Abstract: This invention provides constructs comprising a protein scaffold, wherein the scaffold comprises Domain III, Domain IIIa, or Domain IIIb of human serum albumin or a polypeptide having substantial sequence identity to the Domain III, the Domain IIIa, or the Domain IIIb; and a targeting moiety in covalent linkage to the protein scaffold; and a therapeutic moiety and/or an imaging moiety in covalent linkage to the protein scaffold. The scaffold can be modified to tune the serum pharmacokinetics of the construct. In addition to methods of making the constructs, therapeutic, imaging and diagnostic uses of the constructs are also provided.Type: ApplicationFiled: April 7, 2010Publication date: March 29, 2012Applicant: The Regents of the University of CaliforniaInventors: Anna M. Wu, Vania E. Kenanova, Tove Olafsen
-
Publication number: 20120077228Abstract: Methods for producing modified polypeptides containing amino acid analogues are disclosed. The invention further provides purified dihydrofolate reductase polypeptides, produced by the methods of the invention, in which the methionine residues have been replaced with homoallylglycine, homoproparglycine, norvaline, norleucine, cis-crotylglycine, trans-crotylglycine, 2-aminoheptanoic acid, 2-butynylglycine and allylglycine.Type: ApplicationFiled: April 28, 2011Publication date: March 29, 2012Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: David A. Tirrell, Kristi Lynn Kiick
-
Publication number: 20120071632Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.Type: ApplicationFiled: November 23, 2011Publication date: March 22, 2012Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov, Howard Sard, Vishnumurthy Hegde
-
Publication number: 20120059145Abstract: An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an ?-helical moiety, or one or more proline residues.Type: ApplicationFiled: August 31, 2011Publication date: March 8, 2012Applicant: University of Georgia Research Foundation, Inc.Inventor: Elliot ALTMAN
-
Publication number: 20120052087Abstract: An immunogenic composition comprising a siderophore covalently linked to a pharmaceutically acceptable carrier molecule wherein the antigenicity of the siderophore moiety is sufficient to stimulate an immuno-logic response to the siderophore when the composition is circulating in the bloodstream of a human or non-human animal and vaccine.Type: ApplicationFiled: April 20, 2010Publication date: March 1, 2012Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventor: Raymond J. Bergeron, JR.
-
Publication number: 20120046231Abstract: Described herein is a composition and process for synthesizing a human serum albumin (HSA) based plasma replacement composition that includes a polymerized HSA (PolyHSA) that is chemically stabilized by the reduction of Schiff bases. The PolyHSA may have a molecular weight of at least about 100 kDa and may optionally have a cross-linker to HSA molar ratio of at least about 10:1. The PolyHSA composition is useful for restoring a subject's circulatory volume.Type: ApplicationFiled: August 23, 2011Publication date: February 23, 2012Inventors: Andre Francis Palmer, Pedro Cabrales
-
Publication number: 20120040378Abstract: Carisoprodol is a centrally-acting prescription drug of known abuse. Upon ingestion it is rapidly metabolised to meprobamate, also a prescription drug with abuse potential. Current immunoassays are specific for carisoprodol and therefore have a short window of detection and, furthermore, are ineffective at detecting meprobamate. The current invention, underpinned by an antibody specific for meprobamate, overcomes these deficiencies.Type: ApplicationFiled: August 9, 2011Publication date: February 16, 2012Applicant: RANDOX LABORATORIES LIMITEDInventors: Elouard Benchikh, Ivan McConnell, Peter Fitzgerald, Philip Lowry
-
Coenzyme Q10 Nanoparticles, Preparation Method Thereof and Composition Containing Said Nanoparticles
Publication number: 20120041178Abstract: Provided are a coenzyme Q10 nanoparticle, a method of preparing the same and a composition having the nanoparticle. According to the present invention, Coenzyme Q10 may be dissolved in only a water-miscible organic solvent, and easily made into a nano-sized particle and solubilized under a low energy condition, for example, by simple stirring. The coenzyme Q10 may be dispersion-stabilized by an amino acid or protein. The coenzyme Q10 is formed in a nano-sized particle and solubilized, an absorption rate may be increased and simultaneously deliver the amino acid and protein with the nanoparticle. Thus, the coenzyme Q10 nanoparticle can be effectively used in food, cosmetics and medicine.Type: ApplicationFiled: April 6, 2010Publication date: February 16, 2012Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Bong Hyun Chung, Jung Hyun Han -
Publication number: 20120041180Abstract: Modified human plasma polypeptides or Fc and uses thereof are provided.Type: ApplicationFiled: July 18, 2011Publication date: February 16, 2012Applicant: AMBRX, INC.Inventors: Joseph SHEFFER, Thea NORMAN, Richard D. DIMARCHI, Anna-Maria A. HAYS PUTNAM, Feng TIAN, Stephanie CHU, Denise KRAWITZ, Ho Sung CHO
-
Patent number: 8114963Abstract: Fluorescent dye compounds of formula (I) are disclosed. These compounds are useful as they interact with organic compounds in a manner such that excitation with certain wavelengths of light results in fluorescent emission. Detection and/or monitoring of the fluorescence provides a means for the detection or quantification of organic compounds when bound to these fluorescent dye compounds. Formula (I), wherein: each of R, R? and R? is a hydrogen atom, halogen atom or a straight or branched C1-20 alkyl, alkenyl or alkynl group optionally substituted with one or more halogen, hydroxyl, and/or oxy group; rings A, B and C optionally include one or more double bonds; rings B and C are optionally substituted with one or more halogen atoms.Type: GrantFiled: December 3, 2007Date of Patent: February 14, 2012Assignee: Flurotechnics Pty LimitedInventors: Philip John Livingston Bell, Peter Karuso